Scientists are developing a new drug aimed at tackling obesity in cats and dogs, as rising numbers of pets face serious health risks linked to excess weight. The treatment, known as OKV-119, is being developed by biotech firms Okava and Vivani Medical and could be available by 2028 or 2029. Unlike weekly injections used by humans, the drug is delivered via a six-month implant, raising hopes that it could transform pet health management.
